VOR Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
47.9M
+36.1%
35.2M
-2.2%
36.0M
+27.9%
28.1M
-89.8%
274.3M
R&D
25.9M
+47.3%
17.6M
-8.3%
19.2M
+35.7%
14.1M
-94.6%
261.5M
SG&A
21.9M
+24.9%
17.6M
+4.7%
16.8M
+20.1%
14.0M
+9.2%
12.8M
Operating Income
-47853000
-36.1%
-35160000
+2.2%
-35960000
-27.9%
-28107000
+89.8%
-274284000
EBITDA
-47817000
-36.1%
-35132000
+2.2%
-35937000
-27.9%
-28105000
+89.7%
-272247000
Net Income
-62810000
+71.4%
-219585000
-112.7%
1.7B
+312.0%
-812684000
+48.4%
-1573669000
EPS (Basic)
$-1.16
+77.3%
$-5.11
-106.0%
$84.87
+169.8%
$-121.63
+51.6%
$-251.24
EPS (Diluted)
$-1.16
+77.3%
$-5.11
-106.0%
$84.87
+169.8%
$-121.63
+51.6%
$-251.24
Shares (Diluted)
54.3M
+26.3%
43.0M
+111.9%
20.3M
+203.8%
6.7M
+6.7%
6.3M
Vor Biopharma (VOR) โ€” Financials